-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 RPnlj/dgZ35zoikS8mCcTPQlXEDe7YxWXyD1IyoQvscsSfzhkiWvPJ8sa0WHl0Hw
 fMTlYftTdZcpjOSJUh5azA==

<SEC-DOCUMENT>0000950123-09-018028.txt : 20090626
<SEC-HEADER>0000950123-09-018028.hdr.sgml : 20090626
<ACCEPTANCE-DATETIME>20090626165317
ACCESSION NUMBER:		0000950123-09-018028
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20090626
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20090626
DATE AS OF CHANGE:		20090626

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ONCOGENEX PHARMACEUTICALS, INC.
		CENTRAL INDEX KEY:			0000949858
		STANDARD INDUSTRIAL CLASSIFICATION:	IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
		IRS NUMBER:				954343413
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	033-80623
		FILM NUMBER:		09913597

	BUSINESS ADDRESS:	
		STREET 1:		1522 217TH PLACE S.E.
		CITY:			BOTHELL
		STATE:			WA
		ZIP:			98021
		BUSINESS PHONE:		4254879500

	MAIL ADDRESS:	
		STREET 1:		1522 217TH PLACE S.E.
		CITY:			BOTHELL
		STATE:			WA
		ZIP:			98021

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SONUS PHARMACEUTICALS INC
		DATE OF NAME CHANGE:	19950825
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>c87391e8vk.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML>
<HEAD>
<TITLE>Form 8-K</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in">



<DIV style="font-size: 10pt">
<DIV style="width: 100%; border-bottom: 2pt solid black; font-size: 1pt">&nbsp;</DIV>
<DIV style="width: 100%; border-bottom: 1pt solid black; font-size: 1pt">&nbsp;</DIV>


<P align="center" style="font-size: 14pt"><B>UNITED STATES<BR>
SECURITIES AND EXCHANGE COMMISSION<BR>
<FONT style="font-size: 12pt">Washington, D.C. 20549
</FONT></B>

<P align="center" style="font-size: 18pt"><B>FORM 8-K</B>

<P align="center" style="font-size: 12pt"><B>CURRENT REPORT<BR>
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934</B>

<P align="center" style="font-size: 10pt"><B>Date of Report (Date of earliest event reported): June 26, 2009</B>

<P align="center">

<P align="center" style="font-size: 24pt"><B>ONCOGENEX PHARMACEUTICALS, INC.<BR></B>
<FONT style="font-size: 10pt">(Exact name of registrant as specified in its charter)
</FONT>

<TABLE border="0" width="100%" cellspacing="0" cellpadding="0" style="font-size: 10pt; text-align: center">
<TR>
    <TD width="32%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="33%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="32%">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD style="border-bottom: 1px solid #000000"><B>Delaware</B></TD>
    <TD>&nbsp;</TD>
    <TD style="border-bottom: 1px solid #000000"><B>033-80623</B></TD>
    <TD>&nbsp;</TD>
    <TD style="border-bottom: 1px solid #000000"><B>95-4343413</B></TD>
</TR>
<TR valign="top">
    <TD>(State or other Jurisdiction of Incorporation)</TD>
    <TD>&nbsp;</TD>
    <TD>(Commission File Number)</TD>
    <TD>&nbsp;</TD>
    <TD>(IRS Employer Identification No.)</TD>
</TR>
</TABLE>

<TABLE border="0" width="100%" cellspacing="0" cellpadding="0" style="font-size: 10pt; text-align: center">
<TR>
    <TD width="49%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="49%">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD style="border-bottom: 1px solid #000000"><B>1522 217th Place S.E.<BR>Bothell, Washington<BR></B></TD>
    <TD>&nbsp;</TD>
    <TD style="border-bottom: 1px solid #000000"><B>98021</B></TD>
</TR>
<TR valign="top">
    <TD>(Address of Principal Executive Offices)</TD>
    <TD>&nbsp;</TD>
    <TD>(Zip Code)</TD>
</TR>
</TABLE>

<P align="center" style="font-size: 10pt">Registrant&#146;s telephone number, including area code: <B>(425) 686-1500</B>


<TABLE border="0" width="30%" cellspacing="0" cellpadding="0" style="font-size: 10pt; text-align: center">
<TR>
    <TD width="100%">&nbsp;</TD>
</TR>
<TR>
    <TD nowrap style="border-bottom: 1px solid #000000"><B>N/A<BR></B></TD>
</TR>
<TR>
    <TD nowrap>(Former name or former address if changed since last report.)</TD>
</TR>
</TABLE>

<P align="left" style="font-size: 10pt">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:

<P align="left" style="font-size: 10pt">
<FONT face="Wingdings">&#111;</FONT> Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)<BR><BR>
<FONT face="Wingdings">&#111;</FONT> Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)<BR><BR>
<FONT face="Wingdings">&#111;</FONT> Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))<BR><BR>
<FONT face="Wingdings">&#111;</FONT> Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))<BR>


<P>
<DIV style="width: 100%; border-bottom: 1pt solid black; margin-top: 10pt; font-size: 1pt">&nbsp;</DIV>
<DIV style="width: 100%; border-bottom: 2pt solid black; font-size: 1pt">&nbsp;</DIV>

</DIV>

<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt; display: none">1
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in">

<P align="left" style="font-size: 10pt"><B>Item</B>&nbsp;<B>8.01 Other Events.</B>
<BR>
&nbsp;
<BR>
On June&nbsp;26, 2009, OncoGenex Pharmaceuticals, Inc. issued a press release entitled &#147;OncoGenex Pharmaceuticals Files
Shelf Registration Statement.&#148; A copy of the press release is filed as Exhibit&nbsp;99.1 and incorporated herein by
reference.


<P align="left" style="font-size: 10pt">Exhibit&nbsp;99.1 to this Form 8-K shall be deemed &#147;filed&#148; and not furnished for purposes of the Securities Exchange Act of
1934, as amended.


<P align="left" style="font-size: 10pt"><B>Item&nbsp;9.01 Financial Statements and Exhibits.</B>


<P align="left" style="font-size: 10pt; text-indent: 2%">(d)&nbsp;Exhibits

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="14%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="81%">&nbsp;</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Exhibit&nbsp;No.
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Description</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top" style="border-top: 1px solid #000000"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">99.1
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Press release of OncoGenex Pharmaceuticals, Inc. dated June&nbsp;26, 2009</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt">&nbsp;



<P align="center" style="font-size: 10pt">&nbsp;







<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt; display: none">2
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in">





<P align="center" style="font-size: 10pt"><B>SIGNATURES</B>



<P align="left" style="font-size: 10pt">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has caused this report to be signed
on its behalf by the undersigned, thereunto duly authorized.



<P align="left" style="margin-left:45%; font-size: 10pt">ONCOGENEX PHARMACEUTICALS, INC.


<P align="left" style="font-size: 10pt">Date: June&nbsp;26, 2009



<P align="left" style="margin-left:45%; font-size: 10pt; margin-top: -11pt"><U>/s/ Stephen Anderson&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>


<DIV align="left" style="margin-left:45%; font-size: 10pt">Stephen Anderson<BR>
Chief Financial Officer and Secretary</DIV>


<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt; display: none">3
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in">



<P><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">



</TABLE>


<P align="center" style="font-size: 10pt"><B>EXHIBIT INDEX</B><BR>
&nbsp;


<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="8%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="87%">&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD nowrap align="left" style="border-bottom: 1px solid #000000"><B>Exhibit No.</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" style="border-bottom: 1px solid #000000"><B>Description</B></TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">99.1
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Press release of OncoGenex Pharmaceuticals, Inc. dated June&nbsp;26, 2009</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt; display: none">4




</DIV>
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>c87391exv99w1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
<TITLE>Exhibit 99.1</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->

<DIV style="font-family: Arial,sans-serif; margin-left: .25in; width: 7.20in">
<IMG src="c87391p87391_01.gif" alt="(LOGO)">

<P align="center" style="font-size: 10pt"><B>OncoGenex Pharmaceuticals Files Shelf Registration Statement</B>



<P align="left" style="font-size: 10pt">BOTHELL, WA, and VANCOUVER &#150; June&nbsp;26, 2009 &#151; OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today that it
has filed a shelf registration statement on Form S-3 with the US Securities and Exchange Commission and an MJDS
prospectus under the multi-jurisdictional disclosure system in the Province of British Columbia.


<P align="left" style="font-size: 10pt">&#147;It is prudent for us to re-establish a three-year shelf registration statement to provide us with the flexibility to
support future opportunities,&#148; said Scott Cormack, President and CEO of OncoGenex. &#147;Our focus remains on securing a
development and commercialization partner for our OGX-011 program. Based on our discussions with potential partners to
date, we believe that a partner would fund most or all of the development costs for our OGX-011 program. Accordingly,
we do not expect to offer at the present time securities under this shelf registration to fund our Phase 3 clinical
trials for OGX-011.&#148;


<P align="left" style="font-size: 10pt">OncoGenex elected to terminate its previous shelf registration statement originally filed in July&nbsp;2007.


<P align="left" style="font-size: 10pt">If declared effective by the SEC and the British Columbia Securities Commission, the shelf registration statement and
MJDS prospectus, respectively, will permit OncoGenex Pharmaceuticals to sell, from time to time over a three year
period in one or more public offerings, shares of its common stock, shares of its preferred stock, warrants to purchase
its common stock or preferred stock or debt securities, or any combination of such securities, for proceeds in the
aggregate amount of up to $100&nbsp;million. The terms of any such future offerings, if any, and the type of equity or debt
securities would be established at the time of the offering.


<P align="left" style="font-size: 10pt">A shelf registration statement relating to these securities has been filed with the SEC and an MJDS prospectus has been
filed with the British Columbia Securities Commission but they have not yet become effective. These securities may not
be sold nor may offers to buy be accepted prior to the time the shelf registration statement becomes effective and a
final receipt has been issued for the MJDS prospectus.


<P align="left" style="font-size: 10pt">This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any
sale of these securities in any state or other jurisdiction in which such offer, solicitation, or sale would be
unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. Any
offering will be made only by means of a prospectus and a related prospectus supplement.


<P align="left" style="font-size: 10pt">A written preliminary prospectus included in the registration statement or MJDS prospectus, when available, and meeting
the requirements of Section&nbsp;10 of the Securities Act of 1933, as amended, may be obtained at the SEC&#146;s website
http://www.sec.gov/ , through OncoGenex&#146; website at http://www.oncogenex.com , or via written request to OncoGenex
Pharmaceuticals, Inc. at OncoGenex Pharmaceuticals, Inc. at 1522 217<SUP style="font-size: 85%; vertical-align: text-top">th</sup> Place SE, Suite&nbsp;100, Bothell,
Washington 98021 U.S.A., Attn: Steve Anderson, Chief Financial Officer, or by telephoning (425)&nbsp;686-1500. In addition,
OncoGenex intends to file a prospectus supplement with the SEC in connection with future offerings, if any, under the
shelf registration statement.


<P align="center" style="font-size: 10pt">Page 1 of 3




<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt; display: none">1
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: Arial,sans-serif; margin-left: .25in; width: 7.20in">





<P align="left" style="font-size: 10pt"><B>About OncoGenex</B>


<P align="left" style="font-size: 10pt">OncoGenex is a biopharmaceutical company committed to the development and commercialization of new therapies that
address unmet needs in the treatment of cancer. OncoGenex has a deep oncology pipeline, with each product candidate
having a distinct mechanism of action and representing a unique opportunity for cancer drug development. OGX-011, the
lead candidate that has completed five Phase 2 clinical trials in prostate, lung and breast cancers, is designed to
inhibit the production of a specific protein associated with treatment resistance; OGX-427 is in Phase 1 clinical
development; SN2310 has completed the Phase 1 clinical trial; and CSP-9222 and OGX-225 are currently in pre-clinical
development.


<P align="left" style="font-size: 10pt">OGX-011, OGX-427 and OGX-225 utilize second-generation antisense technology, licensed from Isis Pharmaceuticals
(NASDAQ: ISIS), to effectively target and inhibit production of specific proteins in tumor cells. OncoGenex and Isis
partnered in the successful discovery of OGX-011, OGX-427 and OGX-225 and with respect to OGX-011, in its initial
development. In 2008, OncoGenex and Isis amended their OGX-011 agreement to provide OncoGenex with sole rights to
OGX-011 and sole responsibility for development and related costs and partnering decisions, subject to financial
obligations to Isis. OncoGenex is also solely responsible for development and related costs and partnering decisions
regarding OGX-427 and OGX-225. Key intellectual property related to OGX-011, OGX-427 and OGX-225 were discovered by the
University of British Columbia and the Vancouver Prostate Centre, and were exclusively licensed to OncoGenex.


<P align="left" style="font-size: 10pt">More information about OncoGenex is available at <U>www.oncogenex.com</U>.


<P align="left" style="font-size: 10pt">This press release contains forward-looking statements and &#145;forward-looking information&#146; within the meaning of the
&#147;safe harbor&#148; provisions of the Private Securities Litigation Reform Act of 1995 and applicable Canadian securities
laws, including statements concerning the shelf registration statement, the timing of any offerings under the shelf
registration statement, the use of proceeds of any potential offerings of securities under the shelf registration
statement, potential partnering of OGX-011, anticipated clinical development activities and timing of these activities.
All statements other than statements of historical fact are statements that could be deemed forward-looking statements.
These statements are based on management&#146;s current expectations and beliefs and are subject to a number of risks,
uncertainties and assumptions that could cause actual results to differ materially from those described in the
forward-looking statements.


<P align="left" style="font-size: 10pt">The potential risks and uncertainties associated with forward-looking statements include, among others, the risks
associated with obtaining partnership and/or funding from third parties or completing a financing necessary to support
the costs and expenses of Phase 3 clinical trials, the timing and costs of clinical trials and regulatory approvals
will be different than management currently anticipates, risks relating to the development, safety and efficacy of
therapeutic drugs and potential applications for these products and the risk factors set forth in the Company&#146;s filings
with the Securities and Exchange Commission, including the Company&#146;s Annual Report on Form 10-K for fiscal year 2008.
The Company undertakes no obligation to update the forward-looking statements contained herein or to reflect events or circumstances occurring after the date hereof, except as required by
applicable securities laws.


<P align="center" style="font-size: 10pt">Page 2 of 3




<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt; display: none">2
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: Arial,sans-serif; margin-left: .25in; width: 7.20in">





<P align="center" style="font-size: 10pt">###



<P align="left" style="font-size: 10pt"><B>OncoGenex Contact:</B>



<P align="left" style="margin-left:45%; font-size: 10pt; margin-top: -11pt"><B>Media and Investor Contact:</B>


<DIV align="left" style="font-size: 10pt">Scott Cormack</DIV>



<P align="left" style="margin-left:45%; font-size: 10pt; margin-top: -11pt">Jason Spark


<DIV align="left" style="font-size: 10pt">President &#038; CEO</DIV>



<P align="left" style="margin-left:45%; font-size: 10pt; margin-top: -11pt">Porter Novelli Life Sciences


<DIV align="left" style="font-size: 10pt">(604)&nbsp;736-3678</DIV>



<P align="left" style="margin-left:45%; font-size: 10pt; margin-top: -11pt">(619) 849-6005


<DIV align="left" style="font-size: 10pt">scormack@oncogenex.com</DIV>



<P align="left" style="margin-left:45%; font-size: 10pt; margin-top: -11pt">jspark@pnlifesciences.com


<P align="center" style="font-size: 10pt">Page 3 of 3



<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt; display: none">3




</DIV>
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>c87391p87391_01.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 c87391p87391_01.gif
M1TE&.#EASP!&`/<``'4``'<!`7H!`7T!`6TW.&@]/G,M+G<H*7DQ,V)#1(`!
M`8(!`84``(8``(<"`H4$!(4("88-#HD!`8H!`8<0$8D3%(H6%XX;&XX='H4B
M(I!049I24IM559Q;6H%Q<8!T=(!V=X9Z>Y=@8)5F99%I::![>ZY\?+9\>[Q\
M>\!_?L."@<2%@\:(A\B+BLJ.CL>2D\.7F,R<G<6EILB@H<RLK-.WM]2RLM:_
MO]K'Q]_,S./1T>?6UNC7U^K:VNW>WN_@X._DX^[EY>_GYO#IZ//LZ_7N[?;P
M[_?R\??S\O?T\_CU]/CV]OGX]_KY^?KZ^OO\_/S]_/W^_?W^_O[^_/[^_@``
M````````````````````````````````````````````````````````````
M`````````````````````````````````````````!+8X!A.T)-T\A+8Q!F4
MH````!4``-$`&@`%]5L`&0`%]````````1F.$````!A;V!+9I)$`724>G```
M````````````````````````````````````````````````````````````
M``````````````````````````````````````````````````````"3=!+6
M\#X`/!4``)#I()$[L/___Y$[IY$#(R4>G````````+,`X!+9A!+:*!+<4)#I
M()$#*)#?&I&://___Y%8I)?O!!+B+)?NR!+:-!+:(```&````!+9^```0```
M`````!+:-!+:(````````;,`X!H`1!F4H"4>G!+<O")P(`)P```"R``"X```
M`````#X`/!+:,+,```$``SH`0U<`7$X`24\`1%,`5W,`7',`>64`=#,`;5P`
M,G,`36T`:68`=&0`+FP`;```````````````````````````````````````
M````````````````````````````````````````````````````````````
M`````````````````````"P`````SP!&```(_P!+"1Q(L*#!@P@3*ES(L*'#
MAQ`C2IQ(L:+%BQ@S:MS(L:/'CR!#BAQ)LJ3)DRA3JES)LJ7+ES!CAF1"Y,</
M)3)SZGSI@T:'#!`@;*"!<V=!(CELT+"1PRC#'3Z<)HR1`0``"QU&_-S`0^H/
M%QL46!50(451J05Y9#B!MF"1#@(`*#C15."/%B>Z[GR!P&J&#1@$".9PI.5-
MASBJ<FA+<(,`!0I2'.110V>1$7$ST.A!I,<)R`!:L-2QX49#M8\7,RYU0H`$
M!1R8#%32H\>0G48X"-[PHXEOWY@%;&#9`8`-AFH53%#08?4,!:\Q_!A(0P/D
M#"^(Y`R^0<GOWST"8__8L7(#@!@+>V10_EIRVR+K)PA@,1"%``T_K?*.&2.`
M@`L[?/<=!P!<4%=*Q:V@$!&.32#!:\>U%0-T"ER@@T!@1<B#;@!T4,1+X4&F
M@H#?%8>!7BFI``!;"`WAF`0.5GA;6Q@H)YQ`.[0PHT#PQ86>2S$\ED$1)/Y6
MW'`KV=!A0IC!^)H`HK5U`P4/*O#C$6<-Y(("`F#P(4M*(`#9"47^9AZ+*OT@
M7)8#M>":@P)D\&-;]CUH`1`*!5$!9`>JA`-T$-Q09A,Y4``!BBDQ4<$%/1@T
M(8Q<<H#G:F$MAP%#82F`0DN?20#!$(,6IX)+CE5&$`][/HDF8^HI-Q=#GRG_
M@.1*8DI0`1%EI@#`K"RI2`-!K2ZG0)2KE5(#!%7..15D&.R($@\71.>=@$,4
MA\!T+M4``'T#%2>LLJL]^III"]D`G8$K3;A<=]_]0$-5^[W$PYH"!?F:`BX4
M2Y"X"O2)T)^>_JI2"@(LUX%O2MS@0E49<%L*$2T(K!(1"`0P':K0"9"OO@.)
M*X&_!]U`(;@FI>`J!BF8H$%<%N0UT`_F51#52B8`<(,2+PJP*<<=N_;:A0N)
M_-K&I106T1`]L-E0:S$*>8(-B/:`P&/]LA0#`"K8*T!S//?LX,<,"8UO*4JT
MD`$.`BF!P@48G*"T$@M;8`$&&X#<`PL;;)!"GYBM_\L#9P:I!4"5?2H1`P9S
MCSI0M1I@"S/;1!=4-@9L$RO0E!!$>Y^S/-O[(-`*_0E9##C'==P2/V$008=9
MNA@7`HX)8`&Y9+-0P555"7`"MB-0R+5!.ER0@0LU*D![#QL$D$%@`.R<0U44
M=&4$`AE,K7'@&B@?F``O$%3Z:Q?0WG4I-$#W&MI!0U;!#2)#=MS"7;DI0(1D
M$[@F#05OG?8)^N7@0VL`0$!A3%`P!6A`:3?(0`=P8A\%:*@J*&@"$\QS@:ZH
M2`$8Z,$$$2`0`F5@9@(1G`N:,`3Q:*=;#^+>^`AR@PA426()J<&Y?G"LU^3@
M!W(2R&<$X)Y2V.`Q%:@,#?_D<J-2!*E+O?$-7%94"OM8BG/DFU/Y%#`#@9B'
M74UHC0(JPP)F_>`&`6A*$1RC`(DMP3P(,-)C&I6V3*UJA3ATE>(4HL5+X0!9
M"OC!#"PPHQKISXJ005+I(H">'Q2/!=_1`60@\`,54*@"4"R(R`1017,)8$2^
MB=5Q6G`='"(I!Q>`3/?J)1A,-@$N5:L7'DDV/KBL"U.1*D4+'Y0#!)A`($PH
M'I*&``'(_$X).F"CT"KX'2/X,6+F@P`;$S))]*"R!69ZC&E8\)@-[""'Y*,0
MT3(5`]\`X0("B`"VAK`>+ZZ0(%L"G]((,H0]E;$4.*`2!%0@@1_U(%JP$8@,
M7S/_2D>Y!@,"PAF7>),!2+%R7UPBG76@E$FQ++`47905"C(PHT=9R2[KT1AP
MQ((F%SP&`Q#0V3D75Z.`*>0%ZKL-#BKP(`QD(`@"`>5K6&11^A5D2Q@D$2J'
M$Y;7_`XA'8#,#'R0T1':9U=LY*0$+B"4CHTLIOAT`1/XMZL9*4$\/B`0!4#6
M-8*]1C4("8L`1G`YELKG=Z#D4I3*!R&$U#&@9!R.O3"(K8,$(916,B1T-E"<
MK=4UG1*@9,_<%\)H22!O<AE!72=TR5)X%(DC+85>/64J1_6R`G71`4M?,R<<
M!E9@/V"I`N9(D!I$`#H5X,%W2C@FLHE)/CTT2&L"VTT._U!H:S<;2(B^MLP)
M8?!`\>&2"<0'RC@U:@=^C-<YIRBK$Q+D!]:;XST?=`&8#J1X=6EG(`TR!`2@
M@(S0!,\BZU(#UR@``I7=%P4V$-@:G!(Z$4BO9!&`K.4,:2`V>`U%!U(K=`%+
M3*\2B%>%@ZCQN8E+'5AF*7H`ER*F#9^\*H5N)-`5G%E@3])AYP8RP(3RQ@E4
M2G0H051`-02(3PDO`(`)S"4!%P3U-1%6"P)<P-+Y/#<P2&(PU2Y%D!RLK$(H
M`L)Z`GN!%Q38+D98#8TS$S$;O``#^JFK0+8'KA]:*0?FN0&)=Z47&R"@@J68
M:EPV@`,>`!`!DVH3EP0`@1/$(/\&8`'`")KPG,#*J3B:VH$2<B2WOX$SM07A
M'P:24I43X-D%2=,!"R(`@>6\T5["PH`)7!`#&L3@!2S0``S1<H.PC"4`5IF+
M<P>B(@0HS3P4L(`*AX`""`!`@2O3`.B4D`)71R!W'0`A06S@::M8Y0+=Q`$&
M7F."1AUAB1G00%404!?S[`Q84*Y*:,A6G%<KNT,G>,V17]0TR'@[+IM&2Q$4
MQH'E;<`%7"U%$6J@X($0X04;0$&?<O`"#FQ@!#48=4QCT($-L""W+;I!#$Z`
M`AC@H#<CL`!D'+!,)MP`WALP00WJN@,:1)('WUW!@1*&MWC7`&>[4AH05@:C
MKSWH0;O_TO=JE$`$(JSS(2\GVT*8$'.%J$?.<&&406@ND9<OH2B6/*C4'E/R
MK\4)?9'5%PUNW4W^(2"2(#%1NY_;`7`*1C`4Z,"1DXX6)2%`M4TP#UE-0DXY
M,Z0&)]B`!C;P-*YSK`<6N-9OH&RYD00I``<UR!%^H'*WMZ4#`0B0;WQ0@?F=
M1%<8J+G?1PIW#GSG:OLU"8$BO'B_FW:$9F*B291`H"I6_O,[L,`&?D.#`$0/
M)3G(^^<C6YP1##P"`@CWZF=/$A<!8'49D&\IA+"#8"[A(%-'2`^,YA#BCV0(
MOQ<"&WL`.MI/1`DV:,''#Y*`ZB?``\8OA0X2$/R"',$#2&=(_P_`GY'A*\0#
M,B@%##ZP^P2`P/D@.4("=-"$'B0@!`:Q+D.$D'V;SS\C'M!]`I$`Z7<$,"4#
M[`=_'R%_1^`;)?!^."`#(0`#1W`#1R`$-``#(%`70A`"(4`#0B!+_%<#,@`"
MY'($'D@#H-,#'Y""`X&`Y!*!(9!^`E&"XH,#H0`"C9(#(``#!4&`VF<:()``
MOZ(#((!_"I@12T"`-P`#"8`V'N!^(6!_/9`#H?`!'\!]I1"%(*`+IO&$/1`*
M[O>$I1`"]Z<+2%@*0U!]9E@9,C"&7WA_0/B&9D@[.`@"0I`#8YB&I0"$9E@*
M67@#02"'[Y>$&%%]69@`O^<!^'<$5/^(`_]'A'I(?T38ASA@?Z;Q`3`@!`D@
M*(PX$(/X*R```O(G`TT0`NQW?TVP?M]'`RB8``/Q??0'`A_0!#>0`"$X@.E7
M`K!8@F7H`4(`B0)HB`TA?SMP!$=PA(#H@PN6`$$`B2'H`31``PG0@!^XA3FP
M?>0Q@3H0@*>8AN/7%!HXB#G0!#+@`4.`?K;X`?;7@@F0@$63`.6HCO8'.D`(
M`QY0"KXXA*BHA<1($0SH&_@(B"4@$/;WC+BXA31PB[CR`;_B`=GX?Q-8CTV@
MC`9)?B$``FLH*.=8BNO(B>R6BP(A?SW0!(Q8?_[8AY4QD`A8"J.H?+_WCP!Y
M?S3`B^EW?P+_L7T]<(N-0H#R!P(RX(66N'U-H8Q1&)3@2(8AD(]#2(TPT`35
M=XOOMY0X<(T#<7])\(8T,(0$<7U"P(OJEX^W2`,R4)!5*9,2,81L*!`S*!!!
M@(<Z$`(A>(UZ6(=E&$PZJ(_I-W[\.!`=>"$2N'M9&`+(Z`%1J(5"D(40R4+R
M6(;5UWR0R#[X5P,%J7[5YX/GB)8188!!()))0!!&$YHC69@PE'U*@(PMN!".
M*!!$0(#F-Y+':!#\9Y#]-P2%$9/`LDS]IYD?X8%#.(PEX(&-Z1"M28.\67DU
M\`$@T'P'D0-8&'X-(0/,>9S469W6>9W8F9W:N9W<V9W>^9W@&9[B!3F>!!$0
"`#L_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
